Skip to main content
. Author manuscript; available in PMC: 2021 Apr 16.
Published in final edited form as: Cell Rep. 2021 Mar 9;34(10):108822. doi: 10.1016/j.celrep.2021.108822

Figure 5. MED1 plays a key role in the response of MMTV-HER2 tumor cells to lapatinib treatment.

Figure 5.

(A) Growth curve of orthotopically xenograft MMTV-HER2 and MMTV-HER2/MMTV-MED1 tumors treated with vehicle control (n = 3) or lapatinib (n = 6).

(B) Representative tumor images from each treatment group at the time of collection. Scale bar: 1 cm.

(C and D) IHC staining of Ki67 in tumor sections (C) and quantification (D). Scale bar: 50 μm.

(E and F) H&E staining analyses of serial lung sections of above mice (E) and quantification of metastatic lesions (F). Scale bar: 2 mm.

(G) Representative FACS analysis results of Lin−CD24+CD29hi CSCs in vehicle- or lapatinib-treated MMTV-HER2 and MMTV-HER2/MMTV-MED1 xenograft tumors.

(H) Limiting dilution analyses of bulk cells from MMTV-HER2 and MMTV-HER2/MMTV-MED1 xenograft tumors after lapatinib treatment. The values are obtained from three independent experiments and shown as mean ± SD. *p < 0.05.